Is BAYRY.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

258 people get BAYRY.PK articles and Market Currents by email alert.

Get email alerts on BAYRY.PK »

HEADLINES:

Why Warren Buffett Sees Opportunity In Europe
Gary Bourgeault • Thu, May 16 • 2 Comments
Bayer AG Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
For Onyx Investors, Long Term Value Collides With Short Term Uncertainty
Brian L. Wilson • Mon, Mar 11
Bayer AG Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
4 Drug Delivery Companies That Deliver For Investors
Ryan's View • Wed, Feb 27
China Biotech In Review: Unnamed China Pharma Buys Bayer's Vacated Bay-Area Campus
ChinaBio Today • Sun, Dec 30, 2012
How Trius Will Undercut Pfizer's Zyvox In The Battle Against MRSA
EricFinance • Sun, Dec 2, 2012 • 7 Comments
Searching For Foreign Local Market Stock Opportunities Through U.S. Pink Sheets Filtering
Richard Shaw • Fri, Nov 30, 2012
Clinical Milestones Aside, The Case For Trius Has Other Angles
Richard Richter • Wed, Nov 14, 2012 • 3 Comments
Bayer AG Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 30, 2012
What George Carlin Taught Us About The Race For New Antibiotics
Austrolib • Mon, Oct 29, 2012 • 2 Comments
IPO Preview: KYTHERA Biopharmaceuticals
IPOdesktop • Wed, Oct 10, 2012 • 1 Comment
Defensive Sector Stocks Offer Superior Returns To Long-Term Investors
David Hunkar • Wed, Oct 10, 2012 • 3 Comments
The Prostate Pipeline Revisited
Bryce Istvan • Tue, Sep 4, 2012 • 5 Comments
Best Dividend Yield And Growth Opportunities From Germany
Guraaf • Mon, Aug 13, 2012 • 29 Comments
Bayer AG Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012
Regeneron's Success Isn't Limited To Eylea
Todd Campbell • Thu, Jul 26, 2012 • 2 Comments
Top-Performing Quantitative Dividend Growth Picks And Pans
Tyson Halsey • Tue, Jul 10, 2012
U.S. Proteins: Poised For Export-Led Growth
Stock Whiz • Fri, Jun 29, 2012 • 4 Comments
15 Transnational Companies With High Operating Income From Emerging Economies
David Hunkar • Mon, Jun 25, 2012 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Is Bayer AG A Good Long-Term Play?
Tactical Investor • Mon, Mar 5, 2012 • 6 Comments
Bayer Evenly Poised; Decision By FDA On Blood-Thinner Xarelto Is Anticipated
Zacks Investment Research • Fri, Sep 16, 2011 • 1 Comment
Risk-Reward Is Balanced at Bayer
Zacks Investment Research • Mon, Jun 13, 2011
Revenues Rise at Bayer
Zacks Investment Research • Tue, Mar 1, 2011
Is Bayer's Blood-Thinner Superior to Warfarin or Not?
Pharmalot • Wed, Nov 3, 2010
Bayer Reports $709 Million in 2009 China Revenues
ChinaBio Today • Thu, Apr 29, 2010
Bayer Seeks Better Than 20% Growth in China
ChinaBio Today • Thu, Feb 18, 2010
Bayer's Deadly Drug Poses Challenge to FDA Safety Policies
Mark Senak • Wed, Feb 20, 2008
Another Safety Review on Tap for Bayer's Trasylol -- FDA Panel
SA Editor Susan Lerner • Tue, Sep 11, 2007
Bayer Ready to Cure Investors’ Headaches -- Barron’s
Roy Mehta • Mon, Sep 3, 2007

Why Warren Buffett Sees Opportunity In Europe
Gary Bourgeault • Thu, May 16 • 2 Comments
For Onyx Investors, Long Term Value Collides With Short Term Uncertainty
Brian L. Wilson • Mon, Mar 11
4 Drug Delivery Companies That Deliver For Investors
Ryan's View • Wed, Feb 27
China Biotech In Review: Unnamed China Pharma Buys Bayer's Vacated Bay-Area Campus
ChinaBio Today • Sun, Dec 30, 2012
How Trius Will Undercut Pfizer's Zyvox In The Battle Against MRSA
EricFinance • Sun, Dec 2, 2012 • 7 Comments
Searching For Foreign Local Market Stock Opportunities Through U.S. Pink Sheets Filtering
Richard Shaw • Fri, Nov 30, 2012
Clinical Milestones Aside, The Case For Trius Has Other Angles
Richard Richter • Wed, Nov 14, 2012 • 3 Comments
What George Carlin Taught Us About The Race For New Antibiotics
Austrolib • Mon, Oct 29, 2012 • 2 Comments
IPO Preview: KYTHERA Biopharmaceuticals
IPOdesktop • Wed, Oct 10, 2012 • 1 Comment
Defensive Sector Stocks Offer Superior Returns To Long-Term Investors
David Hunkar • Wed, Oct 10, 2012 • 3 Comments
The Prostate Pipeline Revisited
Bryce Istvan • Tue, Sep 4, 2012 • 5 Comments
Best Dividend Yield And Growth Opportunities From Germany
Guraaf • Mon, Aug 13, 2012 • 29 Comments
Regeneron's Success Isn't Limited To Eylea
Todd Campbell • Thu, Jul 26, 2012 • 2 Comments
Top-Performing Quantitative Dividend Growth Picks And Pans
Tyson Halsey • Tue, Jul 10, 2012
U.S. Proteins: Poised For Export-Led Growth
Stock Whiz • Fri, Jun 29, 2012 • 4 Comments
15 Transnational Companies With High Operating Income From Emerging Economies
David Hunkar • Mon, Jun 25, 2012 • 1 Comment
Germany Vs. Greece: More Than A Game
Markos Kaminis • Fri, Jun 22, 2012 • 59 Comments
Onyx Pharmaceuticals Offers Upside Beyond Kyprolis
Todd Campbell • Tue, Jun 19, 2012 • 1 Comment
Top 10 Mega Caps To Own Right Now, Get Ready For A Surprise
Retracement • Wed, Jun 13, 2012 • 5 Comments
Buy This Pharma Giant Now For A 30% Return In 2013
Dividend Kings • Wed, May 30, 2012 • 4 Comments

Bayer AG Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Bayer AG Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Bayer AG Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Oct 30, 2012
Bayer AG Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012
Bayer's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
Bayer AG's CEO Presents at JPMorgan Global Healthcare Conference (Transcript)
Sun, Mar 11, 2012
Bayer AG's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Feb 28, 2012
Bayer's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Thu, Oct 27, 2011
Bayer's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
Bayer Aktienges CEO Discusses Q1 2011 Results - Earnings Call Transcript
Fri, Apr 29, 2011
Bayer Aktienges CEO Discusses Q4 2010 Results - Earnings Call Transcript
Mon, Feb 28, 2011
Bayer Aktienges Ads CEO Discusses Q3 2010 Results - Earnings Call Transcript
Mon, Nov 1, 2010
Bayer AG Q2 2010 Earnings Call Transcript
Mon, Aug 2, 2010
Bayer Aktienges Ads Q1 2010 Earnings Call Transcript
Fri, Jun 11, 2010

There are no News articles on BAYRY.PK.

BAYRY.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for BAYRY.PK.

Sector: Industrial Goods

Industry: Chemicals - Major Diversified

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, April 29, 11:10 AM In an effort to broaden its women's contraceptive offerings, Bayer (BAYRY.PK +0.4%) has agreed to buy Conceptus (CPTS +19.5%) for around $1.1B. The company says that within the next 10 business days it will launch a tender offer to acquire all of CPTS's stock at $31, a 20% premium to Friday's close. The deal is expected to close by middle of the year. 1 Comment [Healthcare, M&A, Global & FX, On the Move]
Wednesday, April 17, 8:32 AM Syngenta (SYT) feels the heat as the U.K.'s third largest grocery chain says it is "monitoring the situation very closely" to determine whether bee deaths are cause for banning neonicotinoid pesticides from its supply chain. Two competitors have already eliminated their usage of the chemicals and grocery giant Tesco says it will follow the government's advice on the issue, not exactly a comforting stance for SYT considering the regulatory scrutiny the issue has received (I, II). On the bright (and sell) side, Nomura upgrades the shares to Buy from Hold. Shares -1.2% premarket. Comment!
Tuesday, January 29, 4:56 PM Syngenta (SYT) says there are no grounds for restricting use of its Cruiser insecticide - whose sales exceeded $1B in 2011, or 7.5% of SYT's revenue - after the European Commissioner for Health called for laws controlling the product and sprays from Bayer (BAYRY.PK). SYT says constraints on Cruiser would cause significant loss to farmers and the economy. Comment! [Commodities, Global & FX]
Monday, January 28, 7:50 PM Bayer AG (BAYRY.PK) is being sued for failing to provide disclosures and warnings regarding the health risks associated with its popular contraceptive Mirena, which is an intrauterine device designed to prevent pregnancy for as long as five years. The complaint, filed by a Pennsylvania woman who had to have the device surgically removed after complications, claims the company doesn’t warn that it can become embedded in the body or cause an ectopic pregnancy. Comment! [Healthcare]
Wednesday, January 9, 5:05 PM Bayer (BAYRY.PK) says the FDA has approved Skyla, a new hormone-releasing system that is placed in the uterus for the prevention of pregnancy for up to three years. The product is intended for long-term use for up to three years but may be removed by a healthcare provider at any time. Comment! [Healthcare]
Thursday, January 3, 11:23 AM Bayer (BAYRY.PK) and Onyx Pharmaceuticals (ONXX +0.3%) say that Phase 3 trials of Nexavar tablets in patients with locally advanced or metastatic thyroid cancer has met its primary endpoint showing a statistically significant improvement in survival when compared to a placebo. The data is expected to be presented in an upcoming JPMorgan Healthcare Conference. Comment! [Healthcare]
Friday, November 23, 2012, 11:21 AM A new and potential blockbuster drug from Bayer (BAYRY.PK +4%), Regorafenib, could significantly increase the survival prospects of people with gastrointestinal cancer, according to new research published in U.K. medical journal The Lancet. The study also showed survival rates for patients with metastatic bowel cancer improved by taking the drug as well, though not as significantly. Bayer has tagged Regorafenib as one of its most significant new pipeline products. Comment! [Healthcare, On the Move]
Thursday, November 1, 2012, 1:24 PM A number of firms weigh in on Schiff Nutrition (SHF +0.4%) following yesterdays news of a takeover by Bayer (BAYRY.PK). Imperial Capital cuts it to In-Line, saying that although it doesn't expect any competing offers, SHF still has the opportunity to review unsolicited bids up until November 28th. Gabelli also reduced its rating to Hold, while DA Davidson lowers it to Neutral, noting that further upside is limited. Comment! [Healthcare, M&A]
Thursday, August 30, 2012, 10:47 AM Bayer (BAYRY.PK -0.8%) and Onyx Pharmaceuticals (ONXX -0.2%) say they've submitted a New Drug Application to the FDA for their oral multi-kinase inhibitor regorafenib for the treatment of gastrointestinal tumors in patients whose disease has progressed despite prior treatment. Both companies will jointly promote the drug in the United States, while ONXX will receive a royalty on any future global net sales. Comment! [Healthcare]
Monday, August 27, 2012, 10:02 AM J&J's (JNJ +0.2%) and Bayer's (BAYRY.PK) Xarelto blood thinner significantly cut cardiovascular death, heart attacks and strokes in patients who have suffered a severe heart attack and when used with with standard treatments. The results came from a Phase III trial that was testing Xarelto for use in acute coronary syndrome, for which the companies are trying to receive FDA approval after a rejection in June. (PR) Comment! [Healthcare]
Monday, July 9, 2012, 8:40 AM The FDA grants priority review to Bayer's (BAYRY.PK) and J&J's (JNJ) blood-clotting treatment Xarelto for use against deep vein thrombosis and pulmonary embolism, and the prevention of venous thromboembolism in people who have already had it. However, Bayer withdraws its request to use Xarelto to lower the risk of blood clots in heart-stent patients. Comment! [Healthcare]
Thursday, June 28, 2012, 3:28 AM The FDA grants priority review to a cancer drug from Onyx Pharmaceuticals (ONXX) and Bayer AG (BAYRY.PK), meaning the FDA will review the drug in six months instead of the standard ten. Regorafenib is meant to treat metastatic colorectal cancer for patients in whom the disease has worsened after standard therapy. Comment! [Healthcare]
Monday, June 4, 2012, 6:09 AM More from the American Society of Clinical Oncology meeting: GSK (GSK) presents positive results from late-stage trials of its trametinib and dabrafenib treatments for skin cancer, while Bayer's (BAYRY.PK) regorafenib delays progression of stomach cancer. Comment! [Healthcare, Top Stories]
Wednesday, May 30, 2012, 1:52 PM Ardea Biosciences (RDEA -0.1%) says it's earned a $7.5M milestone payment from Bayer (BAYRY.PK) under the terms of their April 2009 global license agreement to develop and commercialize RDEA's mitogen-activated ERK kinase inhibitor compounds for cancer and other indications. The milestone was triggered by the recent initiation of Phase 2 clinical studies. Separately, Gabelli says it's raised its stake in the company from 7.9% to 8.94%. Comment! [Healthcare, On the Move]
Tuesday, May 29, 2012, 3:33 PM Bayer (BAYRY.PK +1.7%) gains on an upgrade to Outperform at Bernstein, saying the outlook on each of the company's divisions has improved, and it expects the company's FY12 EPS to beat expectations. Comment! [Healthcare, On the Move]

BAYRY.PK Bayer Aktienges Ads

BAYRY.PK

Bayer Aktienges Ads